Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131589) titled 'Xeligekimab in the Early Intervention of Psoriasis Vulgaris' on Sept. 4.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Traditional Chinese and Western Medicine Hospital of Wuhan (Wuhan No1 Hospital)

Condition: psoriasis vulgaris

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-09-04

Target Sample Size: Xeligekimab Injection treatment:20;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=334578

Published by HT Digital Content Services with permission from Health Daily Digest....